Catalyst Pharmaceuticals, Inc.
CPRX
$31.16
$0.020.05%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 221.32M | 214.33M | 217.56M | 208.67M | 197.35M |
| Total Depreciation and Amortization | 38.19M | 37.87M | 37.79M | 37.83M | 37.80M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 15.59M | 17.37M | 20.58M | 3.79M | 261.00K |
| Change in Net Operating Assets | -66.88M | -60.90M | -41.28M | 24.81M | 32.51M |
| Cash from Operations | 208.21M | 208.67M | 234.66M | 275.09M | 267.93M |
| Capital Expenditure | -85.00K | -58.00K | -114.00K | -373.00K | -357.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -85.00K | -58.00K | -114.00K | -373.00K | -357.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 13.18M | 14.67M | 18.78M | 16.96M | 16.78M |
| Repurchase of Common Stock | -41.31M | -27.07M | -1.33M | -1.33M | -1.11M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -4.80M | -4.59M | -4.43M | -13.24M | -13.00M |
| Cash from Financing | -32.93M | -16.99M | 13.02M | 2.39M | 2.68M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 175.20M | 191.62M | 247.56M | 277.11M | 270.25M |